ANIP Earnings Prediction
The chart below shows how ANIP performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ANIP sees a -3.75% change in stock price 10 days leading up to the earnings, and a -0.33% change 10 days following the report. On the earnings day itself, the stock moves by +3.09%. This data can give you a slight idea of what to expect for the next quarter's release.
ANIP Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
190.57M
44.75%
28.48%
Gross Margin
46.02%
-3.88%
-1.79%
Operating Margin
0.70%
-89.43%
-105.27%
Net Margin
-5.39%
-712.50%
-66.91%
EPS
-0.55
-1475.00%
-56.69%
No Data Available
ANIP Earnings Analysis
ANI Pharmaceuticals Inc Corporation (ANIP.O) Earnings Conference Call
Positive
Earnings Beat Expectations: ANI Pharmaceuticals, Inc. beats earnings expectations with reported EPS of $1.63, exceeding expectations of $1.41.
Record Performance Results: The company reported record fourth quarter and full year 2024 results, indicating strong overall performance.
Revenue and EBITDA Guidance Increase: ANI is raising its 2025 guidance for total revenues and adjusted non-GAAP EBITDA, reflecting increased confidence in future performance.
Guidance Revision and Demand: The upward revision in guidance is attributed to higher demand for Cortrophin Gel and a strong start for generics, particularly the launch of Prucalopride with 180-day exclusivity.
Brand Demand Surge: Increased demand for established brands is anticipated in the first quarter, supporting the positive outlook for the company.
Negative
Earnings Beat, Revenue Concerns: Despite beating earnings expectations with an EPS of $1.63 compared to the expected $1.41, there are concerns regarding the overall revenue growth and market conditions.
Product Reliance Concerns: The company raised its 2025 guidance based on higher demand for Cortrophin Gel, but this reliance on a single product raises questions about the sustainability of growth.
Acquisition Integration Challenges: The recent acquisition of Alimera and the addition of YUTIQ and ILUVIEN may not yet show significant contributions to revenue, indicating potential integration challenges.
Generics Market Challenges: The mention of a strong start for generics with the launch of Prucalopride is overshadowed by the competitive landscape and potential pricing pressures in the generics market.
Brand Reliance Risks Growth: The company’s reliance on established brands for revenue growth may indicate a lack of innovation or new product development, which could hinder long-term growth prospects.
ANIP FAQs
How does ANIP typically perform around its earnings report dates?
Is ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ANIP Earning Call Sentiment
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript
ANIP.O
-2.85%Positive
The earnings call summary reveals strong financial performance with record revenues and raised guidance, indicating confidence in future growth. The successful launch of new products and strategic acquisitions further bolster the company's market position. Despite some regulatory and competitive risks, the positive EPS surprise and share buyback program enhance shareholder value. The Q&A section highlights strong demand and growth prospects, though some uncertainties remain. Given the company's small-cap status, the positive outlook and raised guidance suggest a stock price increase of 2% to 8% over the next two weeks.
